Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30884498 | 1.00 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL3231898 | 0.98 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8564234 | 0.91 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL655154 | 0.91 | ATM (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL1238351 | 0.89 | ATM (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL12480829 | 0.88 | ATM (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23957116 | 0.87 | ATM (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13339837 | 0.85 | HDAC3 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL3491381 | 0.84 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23957106 | 0.80 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652180-B1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-11-29 | — | — | EP | claimed |
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | DART NEUROSCIENCE, LLC (US) | 2023-06-27 | — | — | US | claimed |
| US-20220267351-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC | 2022-08-25 | — | — | US | claimed |
| EP-3652180-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | Dart NeuroScience LLC (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | claimed |
| US-20260048059-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANC | WIRTH KLAUS (DE) | 2026-02-19 | — | — | US | disclosed |
| EP-4572766-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-12319702-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | DART NEUROSCIENCE, LLC (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240199643-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024038090-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-3652180-B1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3652180-B1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008057995-A2 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-05-15 | — | — | WO | disclosed |
| US-20080108632-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199643-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | PDE7A, PDE7B, PDE8B | HDAC3 1364/4885HDAC4 432/4885HDAC1 1051/4885 |
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | PDE7A, PDE7B, PDE8B | HDAC3 1364/4885HDAC4 432/4885HDAC1 1051/4885 |
| US-20080108632-A1 | HCV PROTEASE INHIBITORS | SERPINB1, HAVCR2, RNASE1 | HDAC3 1783/4885HDAC4 2022/4885HDAC1 1554/4885 |
| US-20260048059-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANC | FANCF, EPAS1, PDE4C | HDAC3 278/4885HDAC4 69/4885HDAC1 370/4885 |
| US-12319702-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | PDE7A, PDE7B, PDE8B | HDAC3 1364/4885HDAC4 432/4885HDAC1 1051/4885 |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | HDAC3 386/4885HDAC4 858/4885HDAC1 259/4885 |
| US-20220267351-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | PDE7A, PDE7B, PDE8B | HDAC3 1364/4885HDAC4 432/4885HDAC1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.